Yield10 Bioscience Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Yield10 Bioscience stock.
View analyst ratings for Yield10 Bioscience or view top-rated stocks.

Wall Street analysts have given Yield10 Bioscience a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Yield10 Bioscience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Yield10 Bioscience saw a decline in short interest in the month of February. As of February 12th, there was short interest totaling 27,700 shares, a decline of 61.6% from the January 28th total of 72,100 shares. Based on an average daily trading volume, of 262,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.9% of the shares of the stock are sold short.
View Yield10 Bioscience's Short Interest.

Yield10 Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Yield10 Bioscience.

Yield10 Bioscience, Inc. (NASDAQ:YTEN) announced its quarterly earnings results on Tuesday, November, 17th. The specialty chemicals company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by $0.06. The specialty chemicals company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.23 million. Yield10 Bioscience had a negative net margin of 1,861.39% and a negative trailing twelve-month return on equity of 347.89%.
View Yield10 Bioscience's earnings history.

Yield10 Bioscience's stock was trading at $4.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, YTEN shares have increased by 201.5% and is now trading at $14.53.
View which stocks have been most impacted by COVID-19.

Yield10 Bioscience's stock reverse split before market open on Thursday, January 16th 2020. The 1-40 reverse split was announced on Wednesday, January 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 15th 2020. An investor that had 100 shares of Yield10 Bioscience stock prior to the reverse split would have 3 shares after the split.

3 brokerages have issued 12 month price objectives for Yield10 Bioscience's shares. Their forecasts range from $15.00 to $25.00. On average, they expect Yield10 Bioscience's share price to reach $21.33 in the next year. This suggests a possible upside of 46.8% from the stock's current price.
View analysts' price targets for Yield10 Bioscience or view top-rated stocks among Wall Street analysts.

Some companies that are related to Yield10 Bioscience include BrasilAgro - Companhia Brasileira de Propriedades Agrícolas (LND), Cresud Sociedad Anónima Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY), AMAYA Global (AYAG), Alico (ALCO), Charlie's (CHUC), Lee Enterprises (LEE), Crimson Wine Group (CWGL), China Liaoning Dingxu Ecological Agriculture Development (CLAD), Educational Development (EDUC), Bridgford Foods (BRID), TDH (PETZ), S&W Seed (SANW), Origin Agritech (SEED), Blue Apron (APRN) and Ocean Bio-Chem (OBCI).
View all of YTEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Yield10 Bioscience investors own include KushCo (KSHB), (CGC), OPKO Health (OPK), T2 Biosystems (TTOO), FuelCell Energy (FCEL), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Rigel Pharmaceuticals (RIGL), (SCON) and Advanced Micro Devices (AMD).

Yield10 Bioscience trades on the NASDAQ under the ticker symbol "YTEN."

Yield10 Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cannell Peter B & Co. Inc. (3.14%) and Renaissance Technologies LLC (0.92%). Company insiders that own Yield10 Bioscience stock include Jack W Schuler and Oliver P Peoples.
View institutional ownership trends for Yield10 Bioscience.

YTEN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Yield10 Bioscience or view top insider-selling stocks.

YTEN stock was purchased by a variety of institutional investors in the last quarter, including Cannell Peter B & Co. Inc.. Company insiders that have bought Yield10 Bioscience stock in the last two years include Jack W Schuler, and Oliver P Peoples.
View insider buying and selling activity for Yield10 Bioscience or or view top insider-buying stocks.

Shares of YTEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of YTEN stock can currently be purchased for approximately $14.53.

Yield10 Bioscience has a market capitalization of $66.91 million and generates $810,000.00 in revenue each year. The specialty chemicals company earns $-12,960,000.00 in net income (profit) each year or ($35.50) on an earnings per share basis.

Yield10 Bioscience employs 25 workers across the globe.

The official website for Yield10 Bioscience is www.yield10bio.com.

Yield10 Bioscience is headquartered at 19 PRESIDENTIAL WAY, WOBURN MA, 01801.

Yield10 Bioscience's mailing address is 19 PRESIDENTIAL WAY, WOBURN MA, 01801. The specialty chemicals company can be reached via phone at 617-583-1700 or via email at [email protected]